INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium
Calithera Biosciences (Nasdaq: CALA) announced the presentation of preliminary data on the safety and efficacy of arginase inhibitor INCB001158, developed by Incyte Pharmaceuticals, at the ASCO 2021 Gastrointestinal Cancers Virtual Symposium from January 15-17, 2021. The Phase I/II trial focuses on patients with advanced biliary tract cancers, with a presentation available from January 15 at 5:00 a.m. PT. The study is led by Dr. Milind Javle from the University of Texas MD Anderson Cancer Center.
- Presentation of promising preliminary data on INCB001158 at a major oncology symposium.
- Trial focuses on advanced biliary tract cancers, a significant area of unmet medical need.
- Forward-looking statements indicate risks that product candidates may not progress through clinical trials or gain regulatory approval.
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from a trial evaluating the arginase inhibitor INCB001158, which is being developed by Incyte Pharmaceuticals, will be presented in a virtual poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Virtual Symposium taking place January 15-17, 2021.
Presentation details:
Date: Available starting on Friday, January 15 at 5:00 a.m. Pacific Time
Title: A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients with advanced biliary tract cancers
Lead Author: Milind Javle, M.D., University of Texas MD Anderson Cancer Center
Poster Session: Hepatobiliary Cancer, Abstract 311
Additional meeting information and accepted abstracts can be found at the ASCO website www.asco.org.
About Calithera
Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, including the potential for INCB001158 to be developed in combination with therapeutics, such as chemotherapy, the overall advancement and timing of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, and other periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
SOURCE: Calithera Biosciences, Incorporated
CONTACTS:
| Investor Relations: Jennifer McNealey ir@Calithera.com 650-870-1071 Media: Hannah Hurdle hannahhurdle@sambrown.com 805-338-4752 |
FAQ
What are the details of Calithera's presentation at ASCO 2021 related to CALA?
Who is leading the study on INCB001158 presented by Calithera?
What type of cancer is being targeted in the INCB001158 trial by Calithera?
What does Calithera's forward-looking statement imply for investors in CALA?
